Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 29, 2007
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, animal health) and institutions in North America and Europe. Operations are divided into two segments: Healthcare Distribution and Technology.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 29, 2007 |
Nine Months Ended Sep 29, 2007 |
Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Net Sales | $1,505,575 | $4,202,720 | $3,573,127 |
| Gross Profit | $429,330 | $1,234,153 | $1,051,824 |
| Gross Margin % | 28.5% | 29.4% | 29.4% |
| Operating Income | $96,700 | $261,273 | $199,596 |
| Net Income | $59,573 | $136,904 | $100,762 |
| Diluted EPS (Continuing Ops) | $0.66 | $1.75 | $1.34 |
| Operating Cash Flow (9mo) | $149,925 | ||
| Total Debt | $464,185 (as of Sep 29, 2007) | ||
| Cash & Equivalents | $207,458 (as of Sep 29, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20.8% in the quarter and 17.6% year-to-date compared to the prior year. Growth was driven by organic volume increases (particularly in dental consumables and influenza vaccines) and acquisitions.
- Profitability: Operating income rose 54.5% in the quarter and 30.9% year-to-date. Net income increased 51.7% in the quarter and 35.9% year-to-date.
- Discontinued Operations: The company divested its oncology pharmaceutical business and classified its specialty pharmacy business as discontinued. This resulted in a $32.7 million impairment charge in Q2 2007 and a net loss from discontinued operations of $21.6 million for the nine months ended September 29, 2007.
- Acquisitions: Significant acquisitions included W&J Dunlop, Ltd. (UK animal health) and Software of Excellence International Ltd. (practice management software), contributing to revenue growth.
- Working Capital: Accounts receivable increased to $764.6 million from $610.0 million, and inventories rose to $676.6 million from $584.1 million, reflecting sales growth and seasonal inventory build-up.
Guidance, Outlook, and Risks
- Tax Outlook: Management expects the effective tax rate to be in the 34% to 35% range for the remainder of 2007 and 35% to 36% for 2008. Recent tax legislation in Germany and the UK resulted in a $3.2 million reduction in deferred tax assets and a $3.5 million non-recurring tax charge.
- Capital Allocation: The company plans to invest $12.0 million to $17.0 million in capital projects for the remainder of the fiscal year. It has $140.5 million remaining under its share repurchase program.
- Liquidity: The company maintains a $300 million revolving credit facility with no borrowings outstanding as of September 29, 2007. Management believes current cash, credit facilities, and access to capital markets are sufficient for foreseeable needs.
- Risks: Key risks include industry consolidation, dependence on third-party suppliers, foreign currency fluctuations, regulatory changes, and the integration of acquired businesses. The company noted that internal controls are undergoing material changes due to recent acquisitions and system implementations.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the final sale price and timeline for the remaining specialty pharmacy business to assess future cash flow impacts.
- Acquisition Integration: Monitor the integration progress of W&J Dunlop and Software of Excellence to ensure anticipated synergies are realized.
- Inventory Levels: Review inventory turnover trends (currently 6.6 turns) to ensure stock levels align with sales velocity and do not indicate obsolescence risks.
- Debt Structure: Confirm the status of the $240 million convertible debt due in 2034 and the $130 million senior notes due in 2009, particularly regarding interest rate exposure.
- Foreign Currency Exposure: Assess the impact of exchange rate fluctuations on the International segment, which contributed significantly to sales growth.